<DOC>
	<DOCNO>NCT00820157</DOCNO>
	<brief_summary>The aim study compare surgical outcome cytoreductive surgery follow Transarterial Chemoembolization ( TACE ) TACE alone patient MNHCC establish treatment standard MNHCC .</brief_summary>
	<brief_title>Cytoreductive Surgery Transarterial Chemoembolization ( TACE ) Versus TACE Hepatocellular Carcinoma</brief_title>
	<detailed_description>Hepatocellular carcinoma ( HCC ) one world 's common malignancy , especially East-Asian country . Hepatic resection accept mean cure patient HCC . The result hepatic resection early-stage HCC favorable.Nevertheless , role surgical resection multinodular HCC ( MNHCC ) less well-defined.The presence multiple tumor show one significant independent factor influence cumulative survival rate HCC hepatic resection.Using BCLC criterion , liver transplantation provide alternative curative treatment option MNHCC size ≤ 5 cm diameter tumor number &lt; 3，but MNHCC beyond criterion usually receive palliative therapy . For MNHCC suitable curative treatment , non-surgical surgical intervention available palliative care.Cytoreductive surgery potential increase quality quantity survival patient advance HCC . Cytoreductive surgery carry partial hepatectomy , cryosurgery , microwave coagulation therapy ( MCT ) , absolute alcohol injection.It show prolong survival provide good symptomatic relief patient good surgical risk non-randomized studies.Cytoreductive surgery aim removal destruction macroscopic tumour , allow microscopic foci persist preserve much functional liver tissue possible . The development effective local ablative therapy ( LAT ) , radiofrequency ablation ( RFA ) therapy , facilitate reduction tumour burden even operation.Cytoreductive surgery also follow non-surgical treatment , regional therapy systemic therapy , deal residual disease micrometastases . The aim study compare surgical outcome cytoreductive surgery follow TACE TACE alone patient MNHCC establish treatment standard MNHCC .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Chlorotrianisene</mesh_term>
	<criteria>Male female patient &gt; 18 year &lt; =70 year age . least 2 radiologic image show characteristic feature HCC one radiologic imaging associate AFP ＞400 cytologic/histologic evidence . tumor number &gt; 3 &lt; =5 , maximum diameter &gt; 5cm &lt; =15cm ; without evidence radiologically definable vascular invasion extrahepatic metastasis . Criteria liver function : Child AB level , serum bilirubin ≤ 1.5 time upper limit normal value , alanine aminotransferase aspartate aminotransferase ≤ 2 time upper limit normal value . No dysfunction major organ ; Blood routine , kidney function , cardiac function lung function basically normal . Hb ≥90g/L , WBC ≥3.000 cells/mm³ , platelet ≥80.000 cells/mm³ Patients understand trial sign information consent Patients apparent cardiac , pulmonary , cerebral renal dysfunction , may affect treatment liver cancer . Patients disease may affect treatment mention . Patients medical history malignant tumor . Subjects participate clinical trial . Extrahepatic metastasis , portal vein major vascular involvement . liver function : Child C. pathological evidence HCC .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>Carcinoma , Hepatocellular</keyword>
	<keyword>Chemoembolization , Therapeutic</keyword>
	<keyword>Cytoreductive</keyword>
</DOC>